Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIAN: ODM-104 PK and BBB Penetration in iNPH Patients
NCT04571996Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neluxicapone in Parkinson's disease (PD), sponsored by Orion Corporation. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Started Oct 2020; status: completed.
02
Drugs
neluxicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04571996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571996.